Adaptin Bio's Cash & cash equivalent grew by 122.53 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Adaptin Bio's Quick Ratio to 0.22, Quick Ratio remained below ADAPTIN BIO, INC. average.

Within Biotechnology & Pharmaceuticals industry ADAPTIN BIO, INC. booked the highest Quick Ratio than Adaptin Bio in the second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 11, from total ranking in the first quarter 2026 at 13.

Explain Quick Ratio?
How much Cash & cash equivalents APTN�s has?
What are APTN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/APTN/financial-strength

https://api.csimarket.com/api/v1/companies/APTN/fundamentals

https://api.csimarket.com/api/v1/companies/APTN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

APTN Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	74.52 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-50.39 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.22	Subscribe	Subscribe	Subscribe	Subscribe
APTN's Total Ranking	# 11	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	8.72 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	122.53 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 0
Healthcare Sector	# 0
Overall Market	# 11

Quick Ratio Statistics
High	Average	Low
1.51	0.45	0
(Jun 30 2024)		(Mar 31 2024)

Financial Statements
Adaptin Bio's Current Liabilities	$ 3 Millions	Visit APTN's Balance sheet
Adaptin Bio's Cash & cash equivalent	$ 1 Millions	Visit APTN's Balance sheet
Source of APTN's Sales		Visit APTN's Sales by Geography

Cumulative Adaptin Bio's Quick Ratio

APTN's Quick Ratio for the trailling 12 Months

APTN Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	42.71 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-49.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.18	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2345	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	13.19 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-25.31 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to APTN Financial Strength Comparisons >> Go to Compare APTN Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $3.04 millions, cumulative Quick Ratio decreased to 0.18 below the Adaptin Bio, Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry APTN achieved the highest Quick Ratio. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 17.

Explain Quick Ratio?
How much Cash & cash equivalents APTN�s has?
What are APTN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 0
Healthcare Sector	# 0
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.76	0.46	0.11
(Dec 31 2025)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Dbv Technologies S a	0.60	$ 23.900 Millions	$ 40.000 Millions
Silexion Therapeutics Corp	0.57	$ 2.258 Millions	$ 3.976 Millions
Atlantic Coastal Acquisition Corp Ii	0.52	$ 4.291 Millions	$ 8.225 Millions
Surrozen Inc	0.50	$ 102.039 Millions	$ 203.292 Millions
Pluri Inc	0.40	$ 13.126 Millions	$ 32.719 Millions
Outlook Therapeutics Inc	0.39	$ 11.242 Millions	$ 28.679 Millions
Neurocrine Biosciences Inc	0.37	$ 390.500 Millions	$ 1,046.100 Millions
Curis Inc	0.37	$ 5.100 Millions	$ 13.675 Millions
Creative Medical Technology Holdings Inc	0.36	$ 0.250 Millions	$ 0.699 Millions
Xtant Medical Holdings Inc	0.33	$ 9.870 Millions	$ 29.963 Millions
BioStem Technologies, Inc.	0.24	$ 6.962 Millions	$ 28.504 Millions
Champions Oncology Inc	0.23	$ 4.358 Millions	$ 18.729 Millions
ADAPTIN BIO, INC.	0.22	$ 0.670 Millions	$ 3.036 Millions
Biogen Inc	0.15	$ 569.400 Millions	$ 3,917.100 Millions
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions
Bioatla Inc	0.06	$ 1.544 Millions	$ 23.951 Millions
Viskase Holdings inc	0.06	$ 7.911 Millions	$ 123.630 Millions
Biomx Inc	0.06	$ 0.585 Millions	$ 10.180 Millions
Tevogen Bio Holdings Inc	0.06	$ 1.082 Millions	$ 19.573 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.